Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: A model-based approach

Diabetes, Obesity and Metabolism

Volumn 10, Issue 12, 2008, Pages 1212-1220

  Xu, L ^a   Man, C Dalla ^b   Charbonnel, B ^c   Meninger, G ^a   Davies, M ^a   Williams Herman, Debora ^a   Cobelli, C ^b   Stein, P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Beta cell function; Dipeptidyl peptidase IV; Incretins; MK 0431

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; METFORMIN; PLACEBO; SITAGLIPTIN;

ADULT; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL;

EID: 55449096196     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00887.x     Document Type: Article

References (24)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
2. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40 (Suppl.): S21-S25.
3. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117: 24-32.
4. Gallwitz B. Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 1654-1661.
5. Drucker DJ, Nauck MA. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006; 368: 1696-1705.
6. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239-245.
7. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
8. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741-750.
9. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther 2005; 78: 675-688.
10. Bergman AJ, Stevens C, Zhou YY et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
11. Kim D, Wang L, Beconi M et al. (2R)-4-oxo-4-[3-(trifluoromethyl -5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-151.
12. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
13. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
14. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 2006; 29: 2638-2643.
15. Scott R, Wu M, Sanchez M, Stein PP. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-180.
16. Rosenstock J, Brazg R, Andryuk P, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-Blind, placebo-controlled parallel group study. Clin Ther 2006; 28: 1556-1568.
17. Breda E, Cobelli C. Insulin secretion rate during glucose stimuli: alternative analyses of C-peptide data. Ann Biomed Eng 2001; 29: 692-700.
18. Brazg R, Xu L, Dalla MC, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-hour glycemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186-193.
19. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
20. Product Information. JANUVIA (sitagliptin). Whitehouse Station, NJ: Merck & Co, Inc, 2006.
21. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 1998; 47: 484-492.
22. Nauck MA, Meininger G, Sheng D, Fanurik D, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
23. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32 (Suppl. 3): 35-45.
24. Yki-Jarvinen H. Acute and chronic effects of hyperglycaemia on glucose metabolism: Implications for the development of new therapies. Diabet Med 1997; 14 (Suppl. 3): S32-S37.